Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917154 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25259084 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25297278 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL29082797 | 0.78 | GAA (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL2105035 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25299888 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25261019 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL18424173 | 0.77 | CYP1A2 (0.73) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL26042174 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL29082769 | 0.76 | CYP1A2 (0.80) | CYP1A2CYP2D6MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368112-B | Therapeutic compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3390402-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | CYP1A2 2139/4885CYP2D6 2379/4885MGLL 2814/4885 |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CYP1A2 2139/4885CYP2D6 2379/4885MGLL 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.